In Very Elderly, Intense Lipid-Lowering Worked in IMPROVE-IT In Very Elderly, Intense Lipid-Lowering Worked in IMPROVE-IT
The post-hoc analysis addresses a gap in the literature, said an expert observer: statin plus ezetimibe safely cut clinical risk in post-ACS patients aged> 75 compared with statin monotherapy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 24, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
Fixed-Dose Bempedoic Acid, Ezetimibe Combo for Statin Intolerance? Fixed-Dose Bempedoic Acid, Ezetimibe Combo for Statin Intolerance?
The fixed-dose combination of the complementary drugs is ' potent and convenient, ' researchers conclude, with statin intolerance potentially ' a very nice niche. 'Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 30, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
Lipitor (atorvastatin) vs. Vytorin (simvastatin and ezetimibe)
Title: Lipitor (atorvastatin) vs. Vytorin (simvastatin and ezetimibe)Category: MedicationsCreated: 5/17/2019 12:00:00 AMLast Editorial Review: 5/17/2019 12:00:00 AM (Source: MedicineNet Cholesterol General)
Source: MedicineNet Cholesterol General - May 17, 2019 Category: Cardiology Source Type: news
Lipitor (atorvastatin) vs. Zetia (ezetimibe)
Title: Lipitor (atorvastatin) vs. Zetia (ezetimibe)Category: MedicationsCreated: 5/17/2019 12:00:00 AMLast Editorial Review: 5/17/2019 12:00:00 AM (Source: MedicineNet Cholesterol General)
Source: MedicineNet Cholesterol General - May 17, 2019 Category: Cardiology Source Type: news
Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review
ANN ARBOR, Mich., May 05, 2019 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) announced today that the U.S. Food and Drug Administration (FDA) has accepted both New Drug Applications for bempedoic acid and the bempedoic acid / ezetimibe combination... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 5, 2019 Category: Drugs & Pharmacology Source Type: news
ezetimibe and simvastatin, Vytorin
Title: ezetimibe and simvastatin, VytorinCategory: MedicationsCreated: 1/31/2005 12:00:00 AMLast Editorial Review: 3/14/2019 12:00:00 AM (Source: MedicineNet Cholesterol General)
Source: MedicineNet Cholesterol General - March 14, 2019 Category: Cardiology Source Type: news
ezetimibe (Zetia)
Title: ezetimibe (Zetia)Category: MedicationsCreated: 2/5/2003 12:00:00 AMLast Editorial Review: 3/1/2019 12:00:00 AM (Source: MedicineNet Cholesterol General)
Source: MedicineNet Cholesterol General - March 1, 2019 Category: Cardiology Source Type: news
Daiichi Sankyo Europe and Esperion Announce Validation of the Marketing Authorisation Application (MAA) for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet
Application is based on results of a robust development programme, which demonstrated that bempedoic acid was well tolerated and efficacious for chronic use
Bempedoic acid is a first-in-class, oral, once-daily ATP Citrate Lyase (ACL) inhibitor that redu... Biopharmaceuticals, Cardiology, Regulatory Daiichi Sankyo, Esperion Therapeutics, bempedoic acid, ezetimibe (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 28, 2019 Category: Pharmaceuticals Source Type: news
Ezetimibe cost saving for prevention of CV events in T2DM
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2019 Category: Drugs & Pharmacology Source Type: news
Adherence and Intensity of Lipid-Lowering Therapy Influences CV Risk
MONDAY, Dec. 17, 2018 -- Adherent patients receiving high-intensity statin and/or ezetimibe therapy have the lowest cardiovascular risk, according to a study published online Dec. 7 in JAMA Network Open.
Kamlesh Khunti, M.D., from the University of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 17, 2018 Category: Pharmaceuticals Source Type: news
Beyond Statins: PCSK9 Inhibitors, Ezetimibe, and Diet Beyond Statins: PCSK9 Inhibitors, Ezetimibe, and Diet
Experts from the Mayo Clinic discuss the spectrum of nonstatin therapies and when they consider using ezetimibe and PCSK9 inhibitors in their patients at high cardiovascular risk.Mayo Clinic (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 30, 2018 Category: Consumer Health News Tags: Cardiology Roundtable Source Type: news
EWTOPIA75: Ezetimibe Reduced First Cardiac Events in Seniors EWTOPIA75: Ezetimibe Reduced First Cardiac Events in Seniors
Japanese patients 75 years and older benefited from this lipid-lowering therapy for the primary prevention of atherosclerotic cardiovascular events.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 23, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news
AHA: Zetia May Cut CV Events in Japanese Seniors
(MedPage Today) -- Results from EWTOPIA75 trial not enough to change practice, experts says (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - November 11, 2018 Category: Pediatrics Source Type: news
Esperion's combo therapy lowers cholesterol level by 35 percent, shares surge
Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Merck's Zetia lowered cholesterol level by 35 percent in a late-stage study, sending the company's shares up as much as 11 percent. (Source: Reuters: Health)
Source: Reuters: Health - August 27, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Esperion says combo therapy lowers cholesterol level by 35 percent
Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Merck's Zetia lowered cholesterol level by 35 percent in a late-stage study. (Source: Reuters: Health)
Source: Reuters: Health - August 27, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
